22:59 , Jul 8, 2019 |  BC Extra  |  Company News

July 8 Company Quick Takes: Merck, Skyhawk in discovery deal; plus MorphoSys, BioMarin, Roche-Spark and Hanmi

Skyhawk, Merck in neurology, cancer deal  Skyhawk Therapeutics Inc. (Waltham, Mass.) and Merck & Co. Inc. (NYSE:MRK) parterned to discover, develop and commercialize small molecules capable of modulating RNA splicing discovered using Skyhawk’s SkySTAR platform...
15:53 , Jul 3, 2019 |  BioCentury  |  Emerging Company Profile

Kymera: a systematic approach to protein degradation

With a computational drug discovery platform and a proprietary library of E3 ligases and binders, Kymera believes it can accelerate the discovery and development of protein degraders. Protein degradation is entering the mainstream as a...
22:24 , May 6, 2019 |  BC Extra  |  Company News

Skyhawk signs neuro deal with Takeda as it prepares to expand its partnered indications

Skyhawk signed its third major deal in a year, this time with Takeda. Like its first two partnerships, the focus will be in neurology, but Skyhawk is in discussions with companies that could help extend...
19:55 , Apr 11, 2019 |  BC Innovations  |  Emerging Company Profile

Nurix: Two sides of protein degradation

Nurix is flipping the concept of targeted protein degradation on its head. In addition to the usual approach of inducing target destruction, the company has technology that can block E3 ligase activity and increase a...
22:35 , Mar 14, 2019 |  BC Extra  |  Company News

Management tracks: Sandoz CEO steps down, C4T hires NIBR's Crystal as CMO

Richard Francis said he will step down as CEO of Sandoz , the biosimilars and generics unit of Novartis AG (NYSE:NVS; SIX:NOVN), effective March 31. Francis said Thursday, "As we announced earlier this year, Sandoz...
18:05 , Jan 11, 2019 |  BC Week In Review  |  Company News

Biogen looks to expand neuro pipeline via C4, Skyhawk deals

A pair of deals announced Jan. 4 leaves Biogen Inc. (NASDAQ:BIIB) poised to expand the druggable space of its neurology pipeline. Biogen entered R&D partnerships with targeted protein degradation company C4 Therapeutics Inc. (Cambridge, Mass.)...
22:03 , Jan 4, 2019 |  BC Extra  |  Company News

Biogen looks to expand neuro pipeline via C4, Skyhawk deals

A pair of deals announced Friday leaves Biogen Inc. (NASDAQ:BIIB) poised to expand the druggable space of its neurology pipeline. Biogen entered R&D partnerships with targeted protein degradation company C4 Therapeutics Inc. (Cambridge, Mass.) and...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
15:59 , Nov 16, 2018 |  BC Week In Review  |  Company News

Dana-Farber, Deerfield launching Center for Protein Degradation

Dana-Farber Cancer Institute and Deerfield Management partnered to create the Center for Protein Degradation, which will be led by Dana-Farber investigators and Harvard Medical School professors Nathanael Gray and Eric Fischer. Located at Dana-Farber, the...
17:13 , Nov 13, 2018 |  BC Extra  |  Company News

Dana-Farber, Deerfield launching Center for Protein Degradation

The Dana-Farber Cancer Institute and Deerfield Management partnered to create the Center for Protein Degradation, which will be led by Dana-Farber investigators and Harvard Medical School professors Nathanael Gray and Eric Fischer. Located at Dana-Farber,...